WO2006121552A3 - Abuse-resistant amphetamine prodrugs - Google Patents

Abuse-resistant amphetamine prodrugs Download PDF

Info

Publication number
WO2006121552A3
WO2006121552A3 PCT/US2006/013221 US2006013221W WO2006121552A3 WO 2006121552 A3 WO2006121552 A3 WO 2006121552A3 US 2006013221 W US2006013221 W US 2006013221W WO 2006121552 A3 WO2006121552 A3 WO 2006121552A3
Authority
WO
WIPO (PCT)
Prior art keywords
abuse
amphetamine
compositions
compounds
bioavailability
Prior art date
Application number
PCT/US2006/013221
Other languages
French (fr)
Other versions
WO2006121552A2 (en
WO2006121552A9 (en
Inventor
Travis Mickle
Suma Krishnan
Barney Bishop
James Scott Moncrief
Christopher Lauderback
Rob Oberlender
Thomas Piccariello
Original Assignee
New River Pharmaceuticals Inc
Travis Mickle
Suma Krishnan
Barney Bishop
James Scott Moncrief
Christopher Lauderback
Rob Oberlender
Thomas Piccariello
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New River Pharmaceuticals Inc, Travis Mickle, Suma Krishnan, Barney Bishop, James Scott Moncrief, Christopher Lauderback, Rob Oberlender, Thomas Piccariello filed Critical New River Pharmaceuticals Inc
Priority to BRPI0612440-2A priority Critical patent/BRPI0612440A2/en
Priority to CA002603873A priority patent/CA2603873A1/en
Priority to US11/400,304 priority patent/US7700561B2/en
Priority to EP06769808A priority patent/EP1865980A4/en
Priority to MX2007012507A priority patent/MX2007012507A/en
Priority to JP2008505617A priority patent/JP2008535860A/en
Publication of WO2006121552A2 publication Critical patent/WO2006121552A2/en
Publication of WO2006121552A9 publication Critical patent/WO2006121552A9/en
Publication of WO2006121552A3 publication Critical patent/WO2006121552A3/en
Priority to US12/202,067 priority patent/US7687467B2/en
Priority to US12/239,180 priority patent/US20090186825A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
PCT/US2006/013221 2002-02-22 2006-04-10 Abuse-resistant amphetamine prodrugs WO2006121552A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0612440-2A BRPI0612440A2 (en) 2005-04-08 2006-04-10 pharmaceutical composition and use of an amphetamine prodrug
CA002603873A CA2603873A1 (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs
US11/400,304 US7700561B2 (en) 2002-02-22 2006-04-10 Abuse-resistant amphetamine prodrugs
EP06769808A EP1865980A4 (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs
MX2007012507A MX2007012507A (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs.
JP2008505617A JP2008535860A (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrug
US12/202,067 US7687467B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/239,180 US20090186825A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US66938505P 2005-04-08 2005-04-08
US66938605P 2005-04-08 2005-04-08
US60/669,385 2005-04-08
US60/669,386 2005-04-08
US68117005P 2005-05-16 2005-05-16
US60/681,170 2005-05-16
US75654806P 2006-01-06 2006-01-06
US60/756,548 2006-01-06
US75995806P 2006-01-19 2006-01-19
US60/759,958 2006-01-19
US11/400,304 2006-04-10

Publications (3)

Publication Number Publication Date
WO2006121552A2 WO2006121552A2 (en) 2006-11-16
WO2006121552A9 WO2006121552A9 (en) 2007-03-08
WO2006121552A3 true WO2006121552A3 (en) 2007-07-05

Family

ID=37397039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013221 WO2006121552A2 (en) 2002-02-22 2006-04-10 Abuse-resistant amphetamine prodrugs

Country Status (6)

Country Link
EP (1) EP1865980A4 (en)
JP (1) JP2008535860A (en)
BR (1) BRPI0612440A2 (en)
CA (1) CA2603873A1 (en)
MX (1) MX2007012507A (en)
WO (1) WO2006121552A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2010042120A1 (en) 2008-10-09 2010-04-15 Archimica, Inc. Process for the synthesis of amphetamine derivatives
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
WO2018118902A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
WO2018118903A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Noncrushable pill formulatiions
DK3459538T3 (en) 2017-09-20 2020-08-03 Sandoz Ag Crystalline salts of a dextroamphetamine prodrug
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
PT3845215T (en) 2019-12-30 2022-10-17 Labomed Pharmaceutical Company S A Oral solutions comprising lisdexamfetamine salts
EP4237007A1 (en) 2020-11-18 2023-09-06 Mind Medicine, Inc. Mdma prodrugs to assist psychotherapy
WO2023111325A1 (en) 2021-12-16 2023-06-22 Labomed Pharmaceutical Company S.A. Container comprising a lisdexamfetamine containing oral solution
WO2024023367A1 (en) 2022-07-29 2024-02-01 Labomed Pharmaceutical Company S.A. Lisdexamfetamine containing oral solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US20050054561A1 (en) * 2002-02-22 2005-03-10 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384020B1 (en) * 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
DE60219005T2 (en) * 2001-05-25 2007-12-13 Cephalon, Inc. Modafinil comprehensive solid pharmaceutical formulations
NZ546226A (en) * 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US20050054561A1 (en) * 2002-02-22 2005-03-10 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1865980A4 *

Also Published As

Publication number Publication date
EP1865980A2 (en) 2007-12-19
EP1865980A4 (en) 2009-11-11
BRPI0612440A2 (en) 2010-11-23
JP2008535860A (en) 2008-09-04
MX2007012507A (en) 2008-03-11
WO2006121552A2 (en) 2006-11-16
CA2603873A1 (en) 2006-11-16
WO2006121552A9 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
BE2020C543I2 (en)
WO2006121552A3 (en) Abuse-resistant amphetamine prodrugs
WO2009036092A9 (en) Mitochondria-targeted anti-tumour agents
GB2419606B (en) Alloyed tungsten produced by chemical vapour deposition
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
WO2006020348A3 (en) Polymorphs of atomoxetine hydrochloride
IL183383A0 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
EA200701687A1 (en) Amorphous hydrochloride lorkanidipine
WO2009035542A3 (en) Guanidine-containing compounds useful as muscarinic receptor antagonists
MX2009008527A (en) Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists.
WO2008140641A3 (en) Pure paliperidone and processes for preparing thereof
WO2005012271A3 (en) Process for the synthesis of biaryl oxazolidinones
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
WO2006038037A3 (en) Improvements in induced heteroduplex generators
WO2009148291A3 (en) 3- or 4-substituted piperidine compounds
WO2006034478A3 (en) Isomigrastatin analogs in the treatment of cancer
WO2005097757A3 (en) Nucleoside derivatives and therapeutic use thereof
WO2010032165A3 (en) Prodrugs of artemisinin
WO2008056059A3 (en) 4-azasterol derivatives, methods for the synthesis thereof and use of same as drugs
WO2007147480A3 (en) Polymorphic forms and process
WO2006019673A3 (en) Jiadifenin analogs and uses thereof
IL187659A0 (en) Process for the preparation of n,n'-disubstituted oxabispidines
TH81376B (en) Pyrazolo-pyrimidine derivative that is mGluR2 antagonist.
TH81376A (en) Pyrazolo-pyrimidine derivative that is mGluR2 antagonist.
FR2903697B1 (en) PROCESSES FOR THE PREPARATION OF FUNCTIONALIZED ORGANOMONOALCOXYSILANES, ESPECIALLY HALOGENES

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680020243.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006769808

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2603873

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008505617

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012507

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3929/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007136824

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0612440

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071008

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: 11/400,304

Country of ref document: US

Date of ref document: 20070116

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED